Get the Daily Brief
Latest Biotech News
AI Advances Enable Highly Precise, Kinetically Controlled Protein Therapeutics
Scientists led by David Baker’s lab at the University of Washington developed a generalizable molecular switch design that precisely modulates protein-protein binding kinetics, increasing...
Gene Therapy Milestone: Uniqure's Huntington's Treatment Slows Disease Progression 75%
Uniqure has announced positive top-line data from the pivotal Phase I/II study of its gene therapy AMT-130 for Huntington's disease, demonstrating a statistically significant 75% slowing in...
Novel Bridge Recombinase System Enables Megabase-Scale Human Genome Editing
Researchers at the Arc Institute have developed a universal bridge recombinase platform that expands gene editing capabilities beyond small mutations to enable large-scale genomic rearrangements...
FDA Approves Lilly's Oral SERD Inluriyo for ESR1-Mutated Breast Cancer
The FDA has cleared Eli Lilly's oral selective estrogen receptor degrader (SERD) Inluriyo (formerly imlunestrant) for treatment of adults with metastatic, estrogen receptor-positive, HER2-negative...
Microchip-Based Peptide Sequencing Enters Commercialization Pathway
Pumpkinseed, a Stanford University spinout, is advancing its silicon chip technology that sequences peptides and analyzes immune cell functionality using Raman spectroscopy. Its platform enables...
Hansa Biopharma's Imlifidase Shows Promise in Kidney Transplant Phase III Trial
Hansa Biopharma has reported positive Phase III trial results for imlifidase, an enzyme that rapidly removes anti-HLA antibodies, enabling highly sensitized kidney transplant patients to receive...
Innovative Peptide Nets Offer New Hope Against Antibiotic-Resistant Bacteria
Biotechnologist Rachel Ee of the National University of Singapore has developed short self-assembling peptides that form microscopic nets in response to bacterial presence, trapping and killing...
UniQure’s AMT-130 Gene Therapy Clinically Validated to Slow Huntington's Disease
UniQure has achieved a pivotal success in Huntington's disease (HD) gene therapy with its AMT-130 candidate, demonstrating a significant 75% reduction in disease progression at 36 months in a...
Lila Sciences Raises $235M to Accelerate AI-Powered Scientific Discovery
Lila Sciences secured $235 million in a Series A round led by Braidwell and Collective Global to scale its AI-driven scientific research platform. The company integrates generative AI, robotics,...
UniQure Gene Therapy’s Pivotal Data Fuels Hope for Huntington's Disease Approval
New clinical data from UniQure's AMT-130 gene therapy reveal a substantial slowing of Huntington's disease progression by 75% over three years in treated patients, meeting the primary composite...
Advances in CRISPR Screening Identify Genetic Tweaks to Boost CAR T Cell Therapies
Mass General Brigham and Broad Institute researchers deployed comprehensive CRISPR screening across the T cell lifecycle to discover gene knockouts enhancing CAR T cell proliferation, persistence,...
uniQure’s Gene Therapy Slows Huntington’s Disease Progression by 75%
UniQure announced positive topline results from its pivotal Phase I/II trial of AMT-130, a gene therapy for Huntington’s disease, demonstrating a statistically significant 75% slowing in disease...
FDA Approves Eli Lilly’s Oral SERD Inluriyo for Advanced Breast Cancer
Eli Lilly’s oral selective estrogen receptor degrader (SERD) Inluriyo (imlunestrant) received FDA approval for treating metastatic estrogen receptor-positive, HER2-negative breast cancer in...
Breakthrough Bridge Recombinase Technology Enables Massive Human Genome Editing
Researchers at the Arc Institute have developed programmable bridge recombinase systems capable of megabase-scale DNA rearrangements in human cells. This technology allows large-scale gene...
Unprecedented AI-Driven Nanoparticle Design Platform Emerges from Duke University
Biomedical engineers at Duke University have integrated automated wet lab techniques with sophisticated artificial intelligence to revolutionize the design of nanoparticles for targeted drug...
Crinetics Pharmaceuticals Gains FDA Nod for Acromegaly Drug Amid Competition
Crinetics Pharmaceuticals earned FDA approval for Palsonify, an oral once-daily treatment for acromegaly in adults ineligible for or unresponsive to surgery. Clinical trials demonstrated...
UniQure’s AMT-130 Gene Therapy Nears First Approval for Huntington’s Disease
Following the pivotal Phase I/II study results showcasing a 75% slowdown in Huntington’s disease progression, UniQure is preparing to seek FDA approval for its gene therapy AMT-130 in early 2026....
Lila Sciences Raises $235M to Propel AI-Driven Scientific Discovery
Lila Sciences secured $235 million in a Series A funding round to develop its AI-powered platform aimed at accelerating drug development by integrating generative AI, robotics, and automated...
Hansa Biopharma’s Imlifidase Shows Success in Phase III Kidney Transplant Trial
Hansa Biopharma reported positive results from a pivotal Phase III trial of imlifidase, an antibody-cleaving enzyme that enables highly sensitized kidney patients to receive transplants. The trial...
STAT+ Reports UK Embraces mRNA Biotech as U.S. Pulls Back Funding
UK officials and researchers are positioning the country as a hub for mRNA-based biotechnology, highlighted by Moderna’s new facility and government support. This contrasts with recent U.S. policy...